The Duchenne community, represented by the World Duchenne Organization, is deeply disappointed to be informed about the recommendation of EMA’s human medicines committee (CHMP) not to renew the Marketing Authorisation for Translarna (ataluren), a medicine for treating patients with Duchenne muscular dystrophy (DMD), which received Conditional Market Authorisation (CMO) in Europe in 2014.
Translarna (ataluren): Devastating news for the Duchenne community
